Scienture Holdings Inc (SCNX) FinancialsSCNXScienture Holdings Inc

Scienture Holdings Inc (SCNX) generates its revenue primarily from Integra pharma, LLC, which accounts for 100.0% of total sales, equivalent to $10.26K. Understanding this concentration is critical for investors evaluating how SCNX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Scienture Holdings Inc maintains a gross margin of 97.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -785.63%, while the net margin is -821.32%. These profitability ratios, combined with a Return on Equity (ROE) of -53.47%, provide a clear picture of how effectively SCNX converts its operational activities into shareholder value.

In the context of the broader market, SCNX competes directly with industry leaders such as JDZG and MGN. With a market capitalization of $5.15M, it holds a significant position in the sector. When comparing efficiency, SCNX's gross margin of 97.71% stands against JDZG's 41.45% and MGN's 11.56%. Such benchmarking helps identify whether Scienture Holdings Inc is trading at a premium or discount relative to its financial performance.

The company has shown some revenue recovery, particularly in Q3 2025 with $590,050, but overall, it has a negative net income trend with significant losses reported in recent quarters. The gross margin has improved to 97.71% in Q2 2026, indicating better cost management, but the overall financial health remains concerning.